Staffurth, John

Abiraterone and Increased Survival in Metastatic Prostate Cancer

de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 4,407

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

Dearnaley, D., Syndikus, I., Mossop, H., Khoo, V., Birtle, A., Bloomfield, D., Graham, J., Kirkbride, P., Logue, J., Malik, Z., et al. (2016) · The Lancet Oncology

Prostate Cancer Diagnosis and TreatmentAdvanced Radiotherapy Techniques

Cited by 1,339

Rucaparib or Physician’s Choice in Metastatic Prostate Cancer

Fizazi, K., Piulats, J. M., Reaume, M. N., Ostler, P., McDermott, R., Gingerich, J. R., Pintus, E., Sridhar, S. S., Bambury, R. M., Emmenegger, U., et al. (2023) · New England Journal of Medicine

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy

Cited by 449